Entries by wp_admin

ARTES, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

Under the title:” devel­op­ment of a virus-like-par­ti­­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions”, in short “Pluri­vax”, the EU coop­er­a­tion is part of the recent 8th Euro­Trans­Bio call and will be fund­ed for a three year peri­od sup­port­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and […]

Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project

ARTES Biotech­nol­o­gy and Bur­net Insti­tute have joined forces to devel­op a new type of malar­ia vac­cine in a project fund­ed by the PATH Malar­ia Vac­cine Ini­tia­tive (MVI). The project will use excit­ing nov­el tech­nol­o­gy devel­oped at the Bur­net Insti­tute. ARTES holds the inter­na­tion­al patent rights and adapt­ed the plat­form to vac­cine pro­duc­tion (known as the […]

Strategic cooperation between ARTES & Sun Pharma

ARTES Biotech­nol­o­gy has entered into a strate­gic col­lab­o­ra­tion with a sub­sidiary of Sun Phar­ma­ceu­ti­cal Indus­tries Ltd, an inter­na­tion­al spe­cial­ty phar­ma­ceu­ti­cal com­pa­ny with a diver­si­fied prod­uct port­fo­lio head­quar­tered in Mumbai/India. This step broad­ens ARTES’ inter­na­tion­al client base and demon­strates its abil­i­ty to attract blue chip phar­ma­ceu­ti­cal com­pa­nies. Under the col­lab­o­ra­tion agree­ment, ARTES will be respon­si­ble to […]

Vaccine Emerging Markets

Meet us at the 2nd Annu­al Pha­cil­i­tate Part­ner­ing for Vac­cine Emerg­ing Mar­kets event in Ams­ter­dam, May 28th -29th or con­tact us pre­vi­ous­ly for a per­son­al meet­ing! We look for­ward to meet­ing you! http://www.phacilitate.co.uk/vaccine-emerging-markets/

EU Research Project “Nano3Bio” has Started – “Huge Potential” through Biotechnology

ARTES Biotech­nol­o­gy GmbH is part of the inter­na­tion­al con­sor­tium While the oil is slow­ly but sure­ly run­ning out, renew­able resources are becom­ing increas­ing­ly impor­tant. In future, the bio­log­i­cal pro­duc­tion of raw mate­ri­als has to play an even greater role to meet the needs in an envi­ron­men­tal­ly friend­ly man­ner. An inter­na­tion­al con­sor­tium of researchers and com­pa­nies […]

ARTES Biotechnology joins TA101 GOCLIN

A lead­ing con­sor­tium of indus­tri­al part­ners has been award­ed a grant by the Sev­enth Frame­work Pro­gram of the Euro­pean Union for an inno­v­a­tive research and devel­op­ment project “TA101 GOCLIN: Clin­i­cal devel­op­ment of TA-101 for the treat­ment of rheuma­toid arthri­tis“ (#606352). The aim of this Project is to take TA101, a small domain anti­body devel­oped by […]

ARTES Biotechnology and Bio Farma announce collaboration in vaccine development

ARTES and Bio Far­ma announced today to join forces for the devel­op­ment and man­u­fac­tur­ing of vac­cine can­di­dates. The agreed col­lab­o­ra­tion involved the strength of both part­ners. ARTES is spe­cial­ized in cell line and process devel­op­ment, VLP based vac­cines as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion process­es where­as Bio Far­ma is involved in […]

ARTES Biotechnology and Midas Pharma signed Cooperation Contract

ARTES announced the col­lab­o­ra­tion with Midas for strate­gic mar­ket­ing oppor­tu­ni­ties. Aim of the coop­er­a­tion is the find­ing of suit­able part­ners for defined phar­ma­ceu­ti­cals projects like vac­cine and phar­ma­ceu­ti­cal tar­get devel­op­ment or trans­fer of Biosim­i­lar process­es. ARTES is spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try where­as […]

ARTES Biotechnology issued New Patent in Australia for VLP Technology

ARTES Biotech­nol­o­gy spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try is pleased to announce the issuance of a new patent for their VLP plat­form. The patent will fur­ther strength­en the Metavax® plat­form of the com­pa­ny. In com­bi­na­tion with the expres­sion plat­form Hansenu­la Metavax® is a unique […]

New website!

ARTES has launched a new web­site, incor­po­rat­ing new con­tent to give a bet­ter view on the cur­rent busi­ness and added offer. The new site espe­cial­ly fea­tures an overview of ARTES’ busi­ness expan­sion in tech­nol­o­gy trans­fer and its Metavax® approach for VLP-based vac­cine devel­op­ment.